Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp>
Lawrence A. Leiter(St. Michael's Hospital), Yehuda Handelsman(Tarzana Treatment Centers), Christopher P. Cannon(University of Massachusetts Chan Medical School), Michael J. Louie(Regeneron (United States)), Maja Bujas‐Bobanovic(Sanofi (France)), José Luis Zamorano(Hospital Universitario Ramón y Cajal), Guillaume Lecorps(Inserm)
Cited by 50
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k